Browsing Category

64152 posts
Everest Medicines' Partner Calliditas Therapeutics Announces Nefecon® the Only FDA-approved Treatment for IgA Nephropathy to Significantly Slow Kidney Function Decline

Everest Medicines' Partner Calliditas Therapeutics Announces Nefecon® the Only FDA-approved Treatment for IgA Nephropathy to Significantly Slow Kidney Function Decline

SHANGHAI, Dec. 21, 2023 /PRNewswire/ — Everest Medicines (HKEX 1952.HK, "Everest", or…
EVERISE ANNOUNCES SUCCESSFUL CLOSURE OF INVESTMENT BY WARBURG PINCUS, JOINING BROOKFIELD FOR THE NEXT PHASE OF GROWTH

EVERISE ANNOUNCES SUCCESSFUL CLOSURE OF INVESTMENT BY WARBURG PINCUS, JOINING BROOKFIELD FOR THE NEXT PHASE OF GROWTH

NEW YORK, SINGAPORE and MUMBAI, Dec. 21, 2023 /PRNewswire/ — Everise, a leading…
ADA Shines Bright at the Prestigious Effie Awards, Securing Gold, Silver, and Bronze Accolades for Exceptional Excellence

ADA Shines Bright at the Prestigious Effie Awards, Securing Gold, Silver, and Bronze Accolades for Exceptional Excellence

COLOMBO, Sri Lanka, Dec. 21, 2023 /PRNewswire/ — ADA, Asia’s largest independent…
Tribesigns Partners with One Tree Planted for Environmental Initiatives

Tribesigns Partners with One Tree Planted for Environmental Initiatives

LOS ANGELES, Dec. 21, 2023 /PRNewswire/ — Tribesigns, a globally acclaimed online…
ENA Building Momentum Globally in Support of Emergency Nurses

ENA Building Momentum Globally in Support of Emergency Nurses

Partnerships help gold standard TNCC and ENPC courses reach more international ED…
Explore AsiaRF's Wireless Innovations at CES 2024, Las Vegas: Tech Excellence Unveiled.

Explore AsiaRF's Wireless Innovations at CES 2024, Las Vegas: Tech Excellence Unveiled.

TAIPEI, Dec. 21, 2023 /PRNewswire/ — AsiaRF, a global leader in wireless…
BioCity announces the first patient dosed with its anti-TIM-3 mAb BC3402 in Combination with IMFINZI for the Treatment of Advanced Hepatocellular Carcinoma in a Phase Ib/II Trial

BioCity announces the first patient dosed with its anti-TIM-3 mAb BC3402 in Combination with IMFINZI for the Treatment of Advanced Hepatocellular Carcinoma in a Phase Ib/II Trial

WUXI, China, Dec. 21, 2023 /PRNewswire/ — BioCity Biopharma today announced dosing…